Vaccinex and the Huntington Study Group (HSG) launched a trial for people with the gene mutation that causes HD who are either early in the progression of the disease or are not yet diagnosed with the disease.
SIGNAL, a Phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab). Pepinemab a monoclonal antibody that is a potential treatment for Huntington’s disease (HD). What-is-hd/overview-of-huntingtons-disease/
On January 16, 2019, Vaccinex, Inc. announced the enrollment was complete and includes two cohorts with a total of 265 Huntington’s Disease subjects – 179 in group 1 (B1) who have early manifest disease and 86 in group 2 (B2) who are late prodromal. All subjects are randomized to receive monthly infusions of either VX15/2503 (pepinemab) or placebo for 18 months in double-blind fashion without crossover.
To read more about the SIGNAL trial, visit http://ir.vaccinex.com/news-releases/news-release-details/vaccinex-inc-announces-completion-enrollment-its-signal
To read FAQ regarding about the trial visit: https://huntingtonstudygroup.org/signal-faq/
Please visit my Author Website to read my blogs about Huntington’s disease and my personal experience https://www.theresecrutchermarin.com
We Can Never Lose HOPE……………….